Berlec A, Ravnikar M, Strukelj B
Department of Biotechnology, Jozef Stefan Institute, Ljubljana, Slovenia.
Pharmazie. 2012 Nov;67(11):891-8.
Lactic acid bacteria (LAB) have become increasingly studied over the last two decades as potential delivery systems for various biological molecules to the gastrointestinal tract. This article presents an overview of characteristics of LAB as delivery systems and of the applications which have already been developed. The majority of LAB strains are able to survive the intestinal passage and some are also able to persist and colonize the intestine. Several strains were in fact described as members of the human commensal flora. They can interact with their host and are able to deliver large molecular weight biomolecules across the epithelium via M-cells or dendritic cells. The most widely applied LAB species has been Lactococcus lactis; however species from genus Lactobacillus are gaining popularity and the first examples from genus Bifidobacterium are starting to emerge. Bacteria are mostly applied live and enable continuous delivery of the biomolecules. However, killed bacteria (e.g. gram-positive enhancer matrix), with bound biomolecules or as adjuvants, are also being developed. The techniques for genetic modification of LAB are well known. This review focuses on the delivery of recombinant proteins and DNA, which can cause either local or systemic effects. We divide recombinant proteins into antigens and therapeutic proteins. Delivery of antigens for the purpose of vaccination represents the most abundant application with numerous successful demonstrations of the efficacy on the animal model. Therapeutic proteins have mostly been developed for the treatment of the inflammatory bowel disease, by the delivery of anti-inflammatory cytokines, or downregulation of proinflammatory cytokines. Delivery of allergens for the modulation of allergic disorders represents the second most popular application of therapeutic proteins. The delivery of DNA by LAB was demonstrated and offers exciting opportunities, especially as a vaccine. New discoveries may eventually lead to the transition of LAB as delivery systems in clinical practice.
在过去二十年中,乳酸菌(LAB)作为将各种生物分子递送至胃肠道的潜在载体,受到了越来越多的研究。本文概述了LAB作为递送系统的特性以及已开发的应用。大多数LAB菌株能够在肠道中存活,有些还能够在肠道中持续存在并定殖。事实上,有几种菌株被描述为人类共生菌群的成员。它们可以与宿主相互作用,并能够通过M细胞或树突状细胞将大分子量生物分子穿过上皮细胞。应用最广泛的LAB物种是乳酸乳球菌;然而,来自乳杆菌属的物种越来越受欢迎,双歧杆菌属的首个例子也开始出现。细菌大多以活的形式应用,能够持续递送生物分子。然而,灭活细菌(如革兰氏阳性增强基质),结合生物分子或作为佐剂,也在开发中。LAB的基因改造技术是众所周知的。本综述重点关注重组蛋白和DNA的递送,它们可引起局部或全身效应。我们将重组蛋白分为抗原和治疗性蛋白。用于疫苗接种目的的抗原递送是最丰富的应用,在动物模型上有许多成功的疗效证明。治疗性蛋白大多是为治疗炎症性肠病而开发的,通过递送抗炎细胞因子或下调促炎细胞因子。用于调节过敏性疾病的过敏原递送是治疗性蛋白的第二大最受欢迎的应用。LAB递送DNA已得到证实,并提供了令人兴奋的机会,尤其是作为疫苗。新的发现最终可能导致LAB作为递送系统在临床实践中的转变。